AU2019371209B2 - Novel dipeptide compounds and uses thereof - Google Patents

Novel dipeptide compounds and uses thereof Download PDF

Info

Publication number
AU2019371209B2
AU2019371209B2 AU2019371209A AU2019371209A AU2019371209B2 AU 2019371209 B2 AU2019371209 B2 AU 2019371209B2 AU 2019371209 A AU2019371209 A AU 2019371209A AU 2019371209 A AU2019371209 A AU 2019371209A AU 2019371209 B2 AU2019371209 B2 AU 2019371209B2
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
ethyl
pharmaceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019371209A
Other languages
English (en)
Other versions
AU2019371209A1 (en
Inventor
Yu Huang
Min Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Synergy Pharmaceutical Sciences Ltd
Original Assignee
Shanghai Synergy Pharmaceutical Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Synergy Pharmaceutical Sciences Ltd filed Critical Shanghai Synergy Pharmaceutical Sciences Ltd
Publication of AU2019371209A1 publication Critical patent/AU2019371209A1/en
Assigned to SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES, LTD. reassignment SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES, LTD. Request for Assignment Assignors: HUAHAI US INC
Application granted granted Critical
Publication of AU2019371209B2 publication Critical patent/AU2019371209B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2019371209A 2018-10-29 2019-10-25 Novel dipeptide compounds and uses thereof Active AU2019371209B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751984P 2018-10-29 2018-10-29
US62/751,984 2018-10-29
PCT/US2019/057985 WO2020092139A1 (en) 2018-10-29 2019-10-25 Novel dipeptide compounds and uses thereof

Publications (2)

Publication Number Publication Date
AU2019371209A1 AU2019371209A1 (en) 2021-05-27
AU2019371209B2 true AU2019371209B2 (en) 2025-05-01

Family

ID=70464360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019371209A Active AU2019371209B2 (en) 2018-10-29 2019-10-25 Novel dipeptide compounds and uses thereof

Country Status (10)

Country Link
US (1) US12209141B2 (https=)
EP (1) EP3873916B8 (https=)
JP (1) JP7503561B2 (https=)
KR (1) KR102882178B1 (https=)
CN (2) CN116813691B (https=)
AU (1) AU2019371209B2 (https=)
CA (1) CA3117599A1 (https=)
IL (1) IL282676B1 (https=)
TW (1) TWI870362B (https=)
WO (1) WO2020092139A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117599A1 (en) * 2018-10-29 2020-05-07 Huahai Us Inc. Novel dipeptide compounds and uses thereof
CN118496301A (zh) * 2023-02-16 2024-08-16 丽珠医药集团股份有限公司 一种二肽类化合物的盐、其制备方法和用途
WO2024169765A1 (zh) * 2023-02-16 2024-08-22 上海华汇拓医药科技有限公司 一种二肽类化合物的盐、其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2639230A1 (en) * 2010-11-08 2013-09-18 Shanghai Institute of Pharmaceutical Industry Prolinamide derivative as thrombin inhibitor, preparation method and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
MX9201416A (es) * 1991-03-28 1992-10-01 Rhone Poulenc Rorer Int Peptidos y pseudopeptidos antitromboticos.
JP4561696B2 (ja) * 1994-01-27 2010-10-13 三菱化学株式会社 プロリンアミド誘導体
FR2793248B1 (fr) * 1999-05-03 2001-06-29 Adir Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6774110B2 (en) * 2001-03-19 2004-08-10 Lg Life Sciences Ltd. Orally available peptidic thrombin inhibitors
FR2836143B1 (fr) * 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1778616A1 (en) * 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
CN100502914C (zh) * 2005-10-24 2009-06-24 丽珠医药集团股份有限公司 一种治疗脑中风的中药组合物及其制备方法
MX2008012574A (es) * 2006-03-29 2008-10-10 Schering Corp Derivados de himbacina monociclitos y biciclicos utiles como antagonistas del receptor de trombina.
CN101784516B (zh) * 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
CN102796168B (zh) * 2011-05-27 2014-02-26 首都医科大学 一种具有溶血栓活性的化合物，及其制备方法和应用
CN103833827B (zh) * 2012-11-27 2016-08-03 上海医药工业研究院 一种酰胺类化合物、其药物组合物、制备方法及应用
AU2014278172B2 (en) * 2013-06-12 2018-08-09 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN106316975A (zh) * 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 酰胺类化合物及其作为tgr5激动剂的应用
CA3117599A1 (en) * 2018-10-29 2020-05-07 Huahai Us Inc. Novel dipeptide compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2639230A1 (en) * 2010-11-08 2013-09-18 Shanghai Institute of Pharmaceutical Industry Prolinamide derivative as thrombin inhibitor, preparation method and application thereof

Also Published As

Publication number Publication date
JP2022509366A (ja) 2022-01-20
KR102882178B1 (ko) 2025-11-05
IL282676A (en) 2021-06-30
US12209141B2 (en) 2025-01-28
JP7503561B2 (ja) 2024-06-20
CN113195515A (zh) 2021-07-30
EP3873916C0 (en) 2025-02-19
US20210395299A1 (en) 2021-12-23
CA3117599A1 (en) 2020-05-07
EP3873916A1 (en) 2021-09-08
EP3873916B8 (en) 2025-03-26
IL282676B1 (en) 2026-03-01
CN116813691A (zh) 2023-09-29
EP3873916A4 (en) 2022-08-10
AU2019371209A1 (en) 2021-05-27
KR20210086682A (ko) 2021-07-08
TW202031674A (zh) 2020-09-01
EP3873916B1 (en) 2025-02-19
TWI870362B (zh) 2025-01-21
CN113195515B (zh) 2024-11-15
CN116813691B (zh) 2024-04-12
WO2020092139A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
ES2263294T3 (es) Amidas antitromboticas.
RU2232760C2 (ru) Ингибитор сериновых протеаз и фармацевтическая композиция на его основе
EP3466961B1 (en) Prolinamide derivative as thrombin inhibitor
CZ245994A3 (en) Piperazides of substituted phenylalanine derivatives as thrombin inhibitors
AU2019371209B2 (en) Novel dipeptide compounds and uses thereof
EP0858262B1 (en) Thrombin inhibitors
CN101421242B (zh) 二酰胺衍生物
AU720803B2 (en) New N-benzylpiperazine compounds, process for their preparation and the pharmaceutical compositions which contain them
US20250179118A1 (en) Novel dipeptide compounds and uses thereof
HK40060683A (en) Novel dipeptide compounds and uses thereof
HK40060683B (en) Novel dipeptide compounds and uses thereof
EP1270569A1 (en) Substituted tryptophan derivatives
CZ200392A3 (cs) Aminoisochinolinové deriváty
HK40094572B (zh) 新的二肽类化合物及其用途
HK40094572A (zh) 新的二肽类化合物及其用途
CN102924567B (zh) 一类肽化合物、其制备方法及用途
CN101724016A (zh) 一类肽化合物、其制备方法及用途
CN101528737B (zh) 新的杂芳基甲酰胺类化合物
JPH0356460A (ja) 健忘症治療剤およびプロリン誘導体
KR100377558B1 (ko) 피페리딘 작용기를 갖는 선택적 트롬빈 억제제
JP2011073993A (ja) 抗凝固作用を有するキノキサリンカルボキサミド誘導体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES, LTD.

Free format text: FORMER APPLICANT(S): HUAHAI US INC

FGA Letters patent sealed or granted (standard patent)